New cancer therapy using genetically-engineered oncolytic Sendai virus vector.

@article{Kinoh2008NewCT,
  title={New cancer therapy using genetically-engineered oncolytic Sendai virus vector.},
  author={Hiroaki Kinoh and Makoto Inoue},
  journal={Frontiers in bioscience : a journal and virtual library},
  year={2008},
  volume={13},
  pages={
          2327-34
        }
}
  • H. Kinoh, M. Inoue
  • Published 2008
  • Biology
  • Frontiers in bioscience : a journal and virtual library
We have developed a new type of Sendai virus-(SeV) based gene transfer vectors for cancer therapy. The matrix gene-, indispensable for particle formation, deficient and fusion gene-, essential for cell-fusion and deciding viral tropism, redesigned SeV vector loses vector particle formation from transduced cells and gains cell-to-cell spreading in protease-dependent, namely controllable, manner. For the selective delivery to malignant tumor cells expressing matrix metalloproteinases (MMPs) or… 

Figures from this paper

Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
TLDR
FUSE-binding protein-interacting repressor (FIR) was found to repress c-myc transcription and in turn the overexpression of FIR drove apoptosis through c- myc suppression, thus FIR expressing vectors are potentially applicable for cancer therapy.
Fusogenic Viruses in Oncolytic Immunotherapy
TLDR
The potential of fusogenic oncolytic viruses as optimal candidates to enhance immunotherapy and initiate broad antitumor responses is discussed, and growing evidence indicates that fusogenicity could be an important feature to consider in the design of optimal onColytic virus platforms for combinatorial on colytic immunotherapy.
Prostate-Specific Antigen-Retargeted Recombinant Newcastle Disease Virus for Prostate Cancer Virotherapy
TLDR
The F protein of NDV was engineered and generated a recombinant NDV whose F protein is cleavable exclusively by prostate-specific antigen (PSA), whose rNDV replicated efficiently and specifically in prostate cancer cells and 3-dimensional prostaspheres but failed to replicate in the absence of PSA.
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency
Oncolytic paramyxoviruses include some strains of Measles, Mumps, Newcastle disease, and Sendai viruses. All these viruses are well equipped for promoting highly specific and efficient malignant cell
Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy
TLDR
The prospects for using paramyxovirus receptors as biomarkers for successful personalized virotherapy for certain types of cancer and a combination of expression signatures of immune and receptor genes could be used to find a set of oncolytic viruses that are more effective for specific malignancies.
Oncolysis by paramyxoviruses: preclinical and clinical studies
TLDR
In general, preclinical studies and phase 1–3 clinical trials yield very encouraging results and warrant continued research of oncolytic paramyxoviruses as a particularly valuable addition to the existing panel of cancer-fighting approaches.
Measles virus for cancer therapy.
  • S. Russell, K. Peng
  • Medicine, Biology
    Current topics in microbiology and immunology
  • 2009
TLDR
An attenuated vaccine strains of measles virus have adapted to use CD46, a regulator of complement activation that is expressed in higher abundance on human tumor cells than on their nontransformed counterparts, and are potent and selective oncolytic agents showing impressive antitumor activity in mouse xenograft models.
Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma
TLDR
The results demonstrate that VSV is a promising oncolytic agent against PDA, and further studies are needed to better understand the molecular mechanisms of resistance of some PDAs to on colytic virotherapy.
Targeted Oncolytic Virotherapy Using Newcastle Disease Virus Against Prostate Cancer
TLDR
The fusion (F) glycoprotein of NDV is engineered and generated a recombinant NDV (rNDV) cleavable exclusively by prostate specific antigen (PSA), which replicated efficiently and specifically only in prostate cancer (CaP) cells but failed to replicate in the absence of PSA.
Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes
TLDR
This review describes and analyses virus adaptation studies performed with members of four RNA virus families that are used for viral oncolysis: reoviruses, paramyxovIRuses, enterovirus, and rhabdoviruse.
...
1
2
...

References

SHOWING 1-10 OF 23 REFERENCES
Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases
TLDR
These results demonstrate the selective targeting and killing of human tumor cells by recombinant SeV technology and greatly advance the reemerging concept of oncolytic virotherapy, which currently appears to rely largely upon a natural preference of certain viruses for cancer cells.
A New Sendai Virus Vector Deficient in the Matrix Gene Does Not Form Virus Particles and Shows Extensive Cell-to-Cell Spreading
TLDR
SeV/ΔM is a novel type of vector with the characteristic features of loss of virus particle formation and gain of cell-to-cell spreading via a mechanism dependent on the activation of the fusion protein.
Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors through Efficient Interleukin-2 Gene Transfer in Vaccinated Rats
TLDR
The present results show that the recombinant nontransmissible SeV vector provides efficient in vivo gene transfer that induces significant regression of the established brain tumors and suggest that it will be a safe and useful viral vector for the clinical practice of glioma gene therapy.
Sendai virus for gene therapy and vaccination.
TLDR
Data on the use of SeV for gene therapy and vaccination since January 2004 are reviewed and recent improvements in SeV vectorology are discussed.
A Cytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus with Efficient Gene Transfer and Expression
TLDR
A virion from defective cDNA of Sendai virus (SeV) that is capable of self-replication but incapable of transmissible-virion production is recovered and it is suggested that this vector has great potential for use in human gene therapy and vaccine delivery systems.
Sendai virus vectors as an emerging negative‐strand RNA viral vector system
TLDR
The murine parainfluenza virus type I, or Sendai virus (SeV), has emerged as a prototype virus of this vector group, being employed in numerous in vitro as well as animal studies over the last few years.
Efficient gene transfer to airway epithelium using recombinant Sendai virus
TLDR
It is shown that recombinant Sendai virus (SeV) produces efficient transfection throughout the respiratory tract of both mice and ferrets in vivo, as well as in freshly obtained human nasal epithelial cells in vitro.
Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector
TLDR
It is demonstrated that SeV achieves high-level transgene expression in skeletal muscle, and that hIGF-I gene transfer using SeV vector may therefore have great potential in the treatment of neuromuscular disorders.
Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: roles of conserved residues in cell fusion
The role of residues in the conserved hydrophobic N-terminal fusion peptide of the paramyxovirus fusion (F) protein in causing cell-cell fusion was examined. Mutations were introduced into the cDNA
Recombinant Sendai virus vectors deleted in both the matrix and the fusion genes: efficient gene transfer with preferable properties
Sendai virus (SeV) is a new type of cytoplasmic RNA vector, which infects and replicates in most mammalian cells, directs high‐level expression of the genes on its genome and is free from
...
1
2
3
...